FDA Updates Highlighting the Latest Cancer Treatments : Oncology Times
An abstract is unavailable.
An abstract is unavailable.
An Overview of MOA, Clinical Data, and Dosing Considerations
TWEAK secreted by Th17 cells promotes EMT by binding to Fn14 on colorectal cancer cells, suggesting that blocking the TWEAK-Fn14 interaction may be a promising…
Summary: . Pathogenic shifts in the gut microbiota are part of the “ecological” alterations that accompany tumor progression and compromise immunosurveillance. The future management of…
The phase 1 trial is evaluating MEM-288 in combination with nivolumab
Nivolumab monotherapy plus salvage nivolumab/ipilimumab demonstrated superior treatment-free survival rates among patients with advanced renal cell carcinoma, especially in patients with favorable risk profiles.
Moffitt gynecologic oncologist joins team of veterinarians and USF physicians to deliver an endangered Bornean orangutan via cesarean section.
Glecirasib elicited responses and demonstrated a manageable safety profile in patients with pretreated advanced NSCLC harboring KRAS G12C mutations.
Venture beyond current limits with our latest perspectives in ovarian cancer care. Learn about new treatments, improving patient outcomes.
Noted physician-scientist studies molecular underpinnings of cardiovascular disease
Should cancer patients avoid sugar? Senior research dietitian Erma Levy explains what you should know about sugar consumption during cancer treatment.